Type 2 diabetes mellitus (DM2) affects a 13.8% of the Spanish population1 and its prevalence is expected to increase in the future.2 The presence of DM2 increases significantly the risk of cardiovascular events, chronic kidney disease (CKD), and premature death3,4 and as its prevalence increases it is expected to rise the incidence of microvascular and macrovascular complications.5 Until the last decade, the control of blood glucose, blood pressure, dyslipidemia, and the use of inhibitors of the renin-angiotensin system (iSRA) have been the only strategies available to reduce cardiovascular and renal risk in this population
The likely reasons include weight loss, less fluid retention, and better blood vessel function
symptoms may include headache, dizziness, shakiness and hunger
3 Increased Heart Rate: Higher doses of GLP-1-based therapies have been linked to slight heart rate increases, warranting long-term monitoring
Our program includes both oral and injectable medications to support your weight loss journey